Targeted therapies in retinoblastoma: GD2-directed immunotherapy following autologous stem cell transplantation and evaluation of alternative target B7-H3
Background GD2-directed immunotherapy is highly effective in the treatment of high-risk neuroblastoma (NB), and might be an interesting target also in other high-risk tumors. Methods The German-Austrian Retinoblastoma Registry, Essen, was searched for patients, who were treated with anti-GD2 monoclo...
Gespeichert in:
| Veröffentlicht in: | Cancer Immunology, Immunotherapy Immunotherapy, 2024-01, Vol.73 (1), p.19-19, Article 19 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 19 |
|---|---|
| container_issue | 1 |
| container_start_page | 19 |
| container_title | Cancer Immunology, Immunotherapy |
| container_volume | 73 |
| creator | Eichholz, Thomas Heubach, Florian Arendt, Anne-Marie Seitz, Christian Brecht, Ines B. Ebinger, Martin Flaadt, Tim Süsskind, Daniela Richter, Lisa Hülsenbeck, Isabel Zerweck, Leonie Göricke, Sophia Paulsen, Frank Dombrowski, Frank Flotho, Christian Schönberger, Stefan Ketteler, Petra Schulte, Johannes Lang, Peter |
| description | Background
GD2-directed immunotherapy is highly effective in the treatment of high-risk neuroblastoma (NB), and might be an interesting target also in other high-risk tumors.
Methods
The German-Austrian Retinoblastoma Registry, Essen, was searched for patients, who were treated with anti-GD2 monoclonal antibody (mAb) dinutuximab beta (Db) in order to evaluate toxicity, response and outcome in these patients. Additionally, we evaluated anti-GD2 antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in retinoblastoma cell lines in vitro. Furthermore, in vitro cytotoxicity assays directed against B7-H3 (CD276), a new identified potential target in RB, were performed.
Results
We identified four patients with relapsed stage IV retinoblastoma, who were treated with Db following autologous stem cell transplantation (ASCT). Two out of two evaluable patients with detectable tumors responded to immunotherapy. One of these and another patient who received immunotherapy without residual disease relapsed 10 and 12 months after start of Db. The other patients remained in remission until last follow-up 26 and 45 months, respectively. In vitro
,
significant lysis of RB cell lines by ADCC and CDC with samples from patients and healthy donors and anti-GD2 and anti-CD276-mAbs were demonstrated.
Conclusion
Anti-GD2-directed immunotherapy represents an additional therapeutic option in high-risk metastasized RB. Moreover, CD276 is another target of interest. |
| doi_str_mv | 10.1007/s00262-023-03587-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10798927</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2916503204</sourcerecordid><originalsourceid>FETCH-LOGICAL-c426t-52462e51bc5ab51ba7469f0d593ef2954e48757c0939e05924b980a5a809bbd93</originalsourceid><addsrcrecordid>eNp9kc9u1DAQxi0EosvCC3BAlrhwCUzsOIm5oFKgRarEpZwtJ5mkrhx7sZ1FfRWeFu-mlD8HfLA9np8_z_gj5HkJr0uA5k0EYDUrgPECuGibAh6QTVnxfNSK8iHZAK-gaACqE_Ikxpu8YSDlY3LCW1ZBW_MN-XGlw4QJB5quMeidwUiNowGTcb6zOiY_67f0_AMrBhOwP5BmnhfnV_6Wjt5a_924ieoleesnv0QaE860R2tpCtrFndUu6WS8o9oNFPfaLmvoR6ptwuByuEeajtXQ901xwZ-SR6O2EZ_drVvy9dPHq7OL4vLL-eez08uir1idCsGqmqEou17oLi-6qWo5wiAkx5FJUWHVNqLpQXKJICSrOtmCFroF2XWD5FvybtXdLd2MQ48u12zVLphZh1vltVF_Z5y5VpPfqxIa2UrWZIVXdwrBf1swJjWbeOheO8y_oZgsGyH4YWzJy3_QG7_k7u2RqgVwBlWm2Er1wccYcLyvpgR18F6t3qvsvTp6n-ctefFnH_dXfpmdAb4CMafchOH32_-R_QlYi705</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2916503204</pqid></control><display><type>article</type><title>Targeted therapies in retinoblastoma: GD2-directed immunotherapy following autologous stem cell transplantation and evaluation of alternative target B7-H3</title><source>SpringerLink Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>Springer Nature OA Free Journals</source><creator>Eichholz, Thomas ; Heubach, Florian ; Arendt, Anne-Marie ; Seitz, Christian ; Brecht, Ines B. ; Ebinger, Martin ; Flaadt, Tim ; Süsskind, Daniela ; Richter, Lisa ; Hülsenbeck, Isabel ; Zerweck, Leonie ; Göricke, Sophia ; Paulsen, Frank ; Dombrowski, Frank ; Flotho, Christian ; Schönberger, Stefan ; Ketteler, Petra ; Schulte, Johannes ; Lang, Peter</creator><creatorcontrib>Eichholz, Thomas ; Heubach, Florian ; Arendt, Anne-Marie ; Seitz, Christian ; Brecht, Ines B. ; Ebinger, Martin ; Flaadt, Tim ; Süsskind, Daniela ; Richter, Lisa ; Hülsenbeck, Isabel ; Zerweck, Leonie ; Göricke, Sophia ; Paulsen, Frank ; Dombrowski, Frank ; Flotho, Christian ; Schönberger, Stefan ; Ketteler, Petra ; Schulte, Johannes ; Lang, Peter</creatorcontrib><description>Background
GD2-directed immunotherapy is highly effective in the treatment of high-risk neuroblastoma (NB), and might be an interesting target also in other high-risk tumors.
Methods
The German-Austrian Retinoblastoma Registry, Essen, was searched for patients, who were treated with anti-GD2 monoclonal antibody (mAb) dinutuximab beta (Db) in order to evaluate toxicity, response and outcome in these patients. Additionally, we evaluated anti-GD2 antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in retinoblastoma cell lines in vitro. Furthermore, in vitro cytotoxicity assays directed against B7-H3 (CD276), a new identified potential target in RB, were performed.
Results
We identified four patients with relapsed stage IV retinoblastoma, who were treated with Db following autologous stem cell transplantation (ASCT). Two out of two evaluable patients with detectable tumors responded to immunotherapy. One of these and another patient who received immunotherapy without residual disease relapsed 10 and 12 months after start of Db. The other patients remained in remission until last follow-up 26 and 45 months, respectively. In vitro
,
significant lysis of RB cell lines by ADCC and CDC with samples from patients and healthy donors and anti-GD2 and anti-CD276-mAbs were demonstrated.
Conclusion
Anti-GD2-directed immunotherapy represents an additional therapeutic option in high-risk metastasized RB. Moreover, CD276 is another target of interest.</description><identifier>ISSN: 0340-7004</identifier><identifier>EISSN: 1432-0851</identifier><identifier>DOI: 10.1007/s00262-023-03587-0</identifier><identifier>PMID: 38240863</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Antibody-dependent cell-mediated cytotoxicity ; Autografts ; Cancer Research ; Cell lines ; Cytotoxicity ; Immunology ; Immunotherapy ; Lysis ; Medicine ; Medicine & Public Health ; Monoclonal antibodies ; Neuroblastoma ; Oncology ; Remission ; Retinoblastoma ; Stem cell transplantation ; Tumors</subject><ispartof>Cancer Immunology, Immunotherapy, 2024-01, Vol.73 (1), p.19-19, Article 19</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c426t-52462e51bc5ab51ba7469f0d593ef2954e48757c0939e05924b980a5a809bbd93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10798927/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10798927/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,41096,41464,42165,42533,51294,51551,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38240863$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Eichholz, Thomas</creatorcontrib><creatorcontrib>Heubach, Florian</creatorcontrib><creatorcontrib>Arendt, Anne-Marie</creatorcontrib><creatorcontrib>Seitz, Christian</creatorcontrib><creatorcontrib>Brecht, Ines B.</creatorcontrib><creatorcontrib>Ebinger, Martin</creatorcontrib><creatorcontrib>Flaadt, Tim</creatorcontrib><creatorcontrib>Süsskind, Daniela</creatorcontrib><creatorcontrib>Richter, Lisa</creatorcontrib><creatorcontrib>Hülsenbeck, Isabel</creatorcontrib><creatorcontrib>Zerweck, Leonie</creatorcontrib><creatorcontrib>Göricke, Sophia</creatorcontrib><creatorcontrib>Paulsen, Frank</creatorcontrib><creatorcontrib>Dombrowski, Frank</creatorcontrib><creatorcontrib>Flotho, Christian</creatorcontrib><creatorcontrib>Schönberger, Stefan</creatorcontrib><creatorcontrib>Ketteler, Petra</creatorcontrib><creatorcontrib>Schulte, Johannes</creatorcontrib><creatorcontrib>Lang, Peter</creatorcontrib><title>Targeted therapies in retinoblastoma: GD2-directed immunotherapy following autologous stem cell transplantation and evaluation of alternative target B7-H3</title><title>Cancer Immunology, Immunotherapy</title><addtitle>Cancer Immunol Immunother</addtitle><addtitle>Cancer Immunol Immunother</addtitle><description>Background
GD2-directed immunotherapy is highly effective in the treatment of high-risk neuroblastoma (NB), and might be an interesting target also in other high-risk tumors.
Methods
The German-Austrian Retinoblastoma Registry, Essen, was searched for patients, who were treated with anti-GD2 monoclonal antibody (mAb) dinutuximab beta (Db) in order to evaluate toxicity, response and outcome in these patients. Additionally, we evaluated anti-GD2 antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in retinoblastoma cell lines in vitro. Furthermore, in vitro cytotoxicity assays directed against B7-H3 (CD276), a new identified potential target in RB, were performed.
Results
We identified four patients with relapsed stage IV retinoblastoma, who were treated with Db following autologous stem cell transplantation (ASCT). Two out of two evaluable patients with detectable tumors responded to immunotherapy. One of these and another patient who received immunotherapy without residual disease relapsed 10 and 12 months after start of Db. The other patients remained in remission until last follow-up 26 and 45 months, respectively. In vitro
,
significant lysis of RB cell lines by ADCC and CDC with samples from patients and healthy donors and anti-GD2 and anti-CD276-mAbs were demonstrated.
Conclusion
Anti-GD2-directed immunotherapy represents an additional therapeutic option in high-risk metastasized RB. Moreover, CD276 is another target of interest.</description><subject>Antibody-dependent cell-mediated cytotoxicity</subject><subject>Autografts</subject><subject>Cancer Research</subject><subject>Cell lines</subject><subject>Cytotoxicity</subject><subject>Immunology</subject><subject>Immunotherapy</subject><subject>Lysis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Monoclonal antibodies</subject><subject>Neuroblastoma</subject><subject>Oncology</subject><subject>Remission</subject><subject>Retinoblastoma</subject><subject>Stem cell transplantation</subject><subject>Tumors</subject><issn>0340-7004</issn><issn>1432-0851</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kc9u1DAQxi0EosvCC3BAlrhwCUzsOIm5oFKgRarEpZwtJ5mkrhx7sZ1FfRWeFu-mlD8HfLA9np8_z_gj5HkJr0uA5k0EYDUrgPECuGibAh6QTVnxfNSK8iHZAK-gaACqE_Ikxpu8YSDlY3LCW1ZBW_MN-XGlw4QJB5quMeidwUiNowGTcb6zOiY_67f0_AMrBhOwP5BmnhfnV_6Wjt5a_924ieoleesnv0QaE860R2tpCtrFndUu6WS8o9oNFPfaLmvoR6ptwuByuEeajtXQ901xwZ-SR6O2EZ_drVvy9dPHq7OL4vLL-eez08uir1idCsGqmqEou17oLi-6qWo5wiAkx5FJUWHVNqLpQXKJICSrOtmCFroF2XWD5FvybtXdLd2MQ48u12zVLphZh1vltVF_Z5y5VpPfqxIa2UrWZIVXdwrBf1swJjWbeOheO8y_oZgsGyH4YWzJy3_QG7_k7u2RqgVwBlWm2Er1wccYcLyvpgR18F6t3qvsvTp6n-ctefFnH_dXfpmdAb4CMafchOH32_-R_QlYi705</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>Eichholz, Thomas</creator><creator>Heubach, Florian</creator><creator>Arendt, Anne-Marie</creator><creator>Seitz, Christian</creator><creator>Brecht, Ines B.</creator><creator>Ebinger, Martin</creator><creator>Flaadt, Tim</creator><creator>Süsskind, Daniela</creator><creator>Richter, Lisa</creator><creator>Hülsenbeck, Isabel</creator><creator>Zerweck, Leonie</creator><creator>Göricke, Sophia</creator><creator>Paulsen, Frank</creator><creator>Dombrowski, Frank</creator><creator>Flotho, Christian</creator><creator>Schönberger, Stefan</creator><creator>Ketteler, Petra</creator><creator>Schulte, Johannes</creator><creator>Lang, Peter</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240101</creationdate><title>Targeted therapies in retinoblastoma: GD2-directed immunotherapy following autologous stem cell transplantation and evaluation of alternative target B7-H3</title><author>Eichholz, Thomas ; Heubach, Florian ; Arendt, Anne-Marie ; Seitz, Christian ; Brecht, Ines B. ; Ebinger, Martin ; Flaadt, Tim ; Süsskind, Daniela ; Richter, Lisa ; Hülsenbeck, Isabel ; Zerweck, Leonie ; Göricke, Sophia ; Paulsen, Frank ; Dombrowski, Frank ; Flotho, Christian ; Schönberger, Stefan ; Ketteler, Petra ; Schulte, Johannes ; Lang, Peter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c426t-52462e51bc5ab51ba7469f0d593ef2954e48757c0939e05924b980a5a809bbd93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antibody-dependent cell-mediated cytotoxicity</topic><topic>Autografts</topic><topic>Cancer Research</topic><topic>Cell lines</topic><topic>Cytotoxicity</topic><topic>Immunology</topic><topic>Immunotherapy</topic><topic>Lysis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Monoclonal antibodies</topic><topic>Neuroblastoma</topic><topic>Oncology</topic><topic>Remission</topic><topic>Retinoblastoma</topic><topic>Stem cell transplantation</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eichholz, Thomas</creatorcontrib><creatorcontrib>Heubach, Florian</creatorcontrib><creatorcontrib>Arendt, Anne-Marie</creatorcontrib><creatorcontrib>Seitz, Christian</creatorcontrib><creatorcontrib>Brecht, Ines B.</creatorcontrib><creatorcontrib>Ebinger, Martin</creatorcontrib><creatorcontrib>Flaadt, Tim</creatorcontrib><creatorcontrib>Süsskind, Daniela</creatorcontrib><creatorcontrib>Richter, Lisa</creatorcontrib><creatorcontrib>Hülsenbeck, Isabel</creatorcontrib><creatorcontrib>Zerweck, Leonie</creatorcontrib><creatorcontrib>Göricke, Sophia</creatorcontrib><creatorcontrib>Paulsen, Frank</creatorcontrib><creatorcontrib>Dombrowski, Frank</creatorcontrib><creatorcontrib>Flotho, Christian</creatorcontrib><creatorcontrib>Schönberger, Stefan</creatorcontrib><creatorcontrib>Ketteler, Petra</creatorcontrib><creatorcontrib>Schulte, Johannes</creatorcontrib><creatorcontrib>Lang, Peter</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer Immunology, Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eichholz, Thomas</au><au>Heubach, Florian</au><au>Arendt, Anne-Marie</au><au>Seitz, Christian</au><au>Brecht, Ines B.</au><au>Ebinger, Martin</au><au>Flaadt, Tim</au><au>Süsskind, Daniela</au><au>Richter, Lisa</au><au>Hülsenbeck, Isabel</au><au>Zerweck, Leonie</au><au>Göricke, Sophia</au><au>Paulsen, Frank</au><au>Dombrowski, Frank</au><au>Flotho, Christian</au><au>Schönberger, Stefan</au><au>Ketteler, Petra</au><au>Schulte, Johannes</au><au>Lang, Peter</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeted therapies in retinoblastoma: GD2-directed immunotherapy following autologous stem cell transplantation and evaluation of alternative target B7-H3</atitle><jtitle>Cancer Immunology, Immunotherapy</jtitle><stitle>Cancer Immunol Immunother</stitle><addtitle>Cancer Immunol Immunother</addtitle><date>2024-01-01</date><risdate>2024</risdate><volume>73</volume><issue>1</issue><spage>19</spage><epage>19</epage><pages>19-19</pages><artnum>19</artnum><issn>0340-7004</issn><eissn>1432-0851</eissn><abstract>Background
GD2-directed immunotherapy is highly effective in the treatment of high-risk neuroblastoma (NB), and might be an interesting target also in other high-risk tumors.
Methods
The German-Austrian Retinoblastoma Registry, Essen, was searched for patients, who were treated with anti-GD2 monoclonal antibody (mAb) dinutuximab beta (Db) in order to evaluate toxicity, response and outcome in these patients. Additionally, we evaluated anti-GD2 antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in retinoblastoma cell lines in vitro. Furthermore, in vitro cytotoxicity assays directed against B7-H3 (CD276), a new identified potential target in RB, were performed.
Results
We identified four patients with relapsed stage IV retinoblastoma, who were treated with Db following autologous stem cell transplantation (ASCT). Two out of two evaluable patients with detectable tumors responded to immunotherapy. One of these and another patient who received immunotherapy without residual disease relapsed 10 and 12 months after start of Db. The other patients remained in remission until last follow-up 26 and 45 months, respectively. In vitro
,
significant lysis of RB cell lines by ADCC and CDC with samples from patients and healthy donors and anti-GD2 and anti-CD276-mAbs were demonstrated.
Conclusion
Anti-GD2-directed immunotherapy represents an additional therapeutic option in high-risk metastasized RB. Moreover, CD276 is another target of interest.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>38240863</pmid><doi>10.1007/s00262-023-03587-0</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-7004 |
| ispartof | Cancer Immunology, Immunotherapy, 2024-01, Vol.73 (1), p.19-19, Article 19 |
| issn | 0340-7004 1432-0851 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10798927 |
| source | SpringerLink Journals; PubMed Central; Alma/SFX Local Collection; Springer Nature OA Free Journals |
| subjects | Antibody-dependent cell-mediated cytotoxicity Autografts Cancer Research Cell lines Cytotoxicity Immunology Immunotherapy Lysis Medicine Medicine & Public Health Monoclonal antibodies Neuroblastoma Oncology Remission Retinoblastoma Stem cell transplantation Tumors |
| title | Targeted therapies in retinoblastoma: GD2-directed immunotherapy following autologous stem cell transplantation and evaluation of alternative target B7-H3 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T15%3A24%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeted%20therapies%20in%20retinoblastoma:%20GD2-directed%20immunotherapy%20following%20autologous%20stem%20cell%20transplantation%20and%20evaluation%20of%20alternative%20target%20B7-H3&rft.jtitle=Cancer%20Immunology,%20Immunotherapy&rft.au=Eichholz,%20Thomas&rft.date=2024-01-01&rft.volume=73&rft.issue=1&rft.spage=19&rft.epage=19&rft.pages=19-19&rft.artnum=19&rft.issn=0340-7004&rft.eissn=1432-0851&rft_id=info:doi/10.1007/s00262-023-03587-0&rft_dat=%3Cproquest_pubme%3E2916503204%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2916503204&rft_id=info:pmid/38240863&rfr_iscdi=true |